Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure
Abstract The Centers for Medicare & Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concern...
Gespeichert in:
Veröffentlicht in: | Clinical infectious diseases 2021-02, Vol.72 (4), p.541-552 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 552 |
---|---|
container_issue | 4 |
container_start_page | 541 |
container_title | Clinical infectious diseases |
container_volume | 72 |
creator | Rhee, Chanu Chiotos, Kathleen Cosgrove, Sara E Heil, Emily L Kadri, Sameer S Kalil, Andre C Gilbert, David N Masur, Henry Septimus, Edward J Sweeney, Daniel A Strich, Jeffrey R Winslow, Dean L Klompas, Michael |
description | Abstract
The Centers for Medicare & Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concerned about SEP-1’s potential to drive antibiotic overuse because it does not account for the high rate of sepsis overdiagnosis and encourages aggressive antibiotics for all patients with possible sepsis, regardless of the certainty of diagnosis or severity of illness. IDSA is also concerned that SEP-1’s complex “time zero” definition is not evidence-based and is prone to inter-observer variation. In this position paper, IDSA outlines several recommendations aimed at reducing the risk of unintended consequences of SEP-1 while maintaining focus on its evidence-based elements. IDSA’s core recommendation is to limit SEP-1 to septic shock, for which the evidence supporting the benefit of immediate antibiotics is greatest. Prompt empiric antibiotics are often appropriate for suspected sepsis without shock, but IDSA believes there is too much heterogeneity and difficulty defining this population, uncertainty about the presence of infection, and insufficient data on the necessity of immediate antibiotics to support a mandatory treatment standard for all patients in this category. IDSA believes guidance on managing possible sepsis without shock is more appropriate for guidelines that can delineate the strengths and limitations of supporting evidence and allow clinicians discretion in applying specific recommendations to individual patients. Removing sepsis without shock from SEP-1 will mitigate the risk of unnecessary antibiotic prescribing for noninfectious syndromes, simplify data abstraction, increase measure reliability, and focus attention on the population most likely to benefit from immediate empiric broad-spectrum antibiotics.
This Infectious Diseases Society of America position paper outlines several recommendations aimed at reducing the risk of unintended consequences from the national Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) quality measure, while maintaining focus on its evidence-based elements. |
doi_str_mv | 10.1093/cid/ciaa059 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8189682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciaa059</oup_id><sourcerecordid>2399838578</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-2a94e61bc2f283a4d2f3b300603ae9c4665a98b69f059c614ec13213dde4d1d3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSMEoqVw4o58QkUo4D-J1-4BqZQFKrWwsL1bs_aka0jiYCcr7dfiE-LVbiu4cLBmpPn5zdO8onjO6BtGtXhrvcsPgNb6QXHMajErZa3Zw9zTWpWVEuqoeJLSD0oZU7R-XBwJLmaVkuy4-H3ZN2hHH6ZEPviEkDCRZbAexy0JDTnvMHoLZBGSz1RPFjBgPCPf0Yauw96hy_3GpzxLZAxkXCP5AjsUWrLEDUbMZUg-Eejdrh29Jct1sD_JHGK7JdfQwy1mrZG8n3rXIjldzhcle3X379sErc92rrO7KeLT4lEDbcJnh3pS3Hyc31x8Lq--frq8OL8qbcX4WHLQFUq2srzhSkDleCNWglJJBaC2lZQ1aLWSusmHs5JVaJngTDiHlWNOnBTv9rLDtOrQ2ewvQmuG6DuIWxPAm38nvV-b27AxiiktFc8CpweBGH5NmEbT-WSxbaHHfG7DhdY5m3qmMvp6j9oYUorY3K9h1OxCNjlkcwg50y_-dnbP3qWagZd7IEzDf5X-AM1Gs_c</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399838578</pqid></control><display><type>article</type><title>Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Rhee, Chanu ; Chiotos, Kathleen ; Cosgrove, Sara E ; Heil, Emily L ; Kadri, Sameer S ; Kalil, Andre C ; Gilbert, David N ; Masur, Henry ; Septimus, Edward J ; Sweeney, Daniel A ; Strich, Jeffrey R ; Winslow, Dean L ; Klompas, Michael</creator><creatorcontrib>Rhee, Chanu ; Chiotos, Kathleen ; Cosgrove, Sara E ; Heil, Emily L ; Kadri, Sameer S ; Kalil, Andre C ; Gilbert, David N ; Masur, Henry ; Septimus, Edward J ; Sweeney, Daniel A ; Strich, Jeffrey R ; Winslow, Dean L ; Klompas, Michael</creatorcontrib><description>Abstract
The Centers for Medicare & Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concerned about SEP-1’s potential to drive antibiotic overuse because it does not account for the high rate of sepsis overdiagnosis and encourages aggressive antibiotics for all patients with possible sepsis, regardless of the certainty of diagnosis or severity of illness. IDSA is also concerned that SEP-1’s complex “time zero” definition is not evidence-based and is prone to inter-observer variation. In this position paper, IDSA outlines several recommendations aimed at reducing the risk of unintended consequences of SEP-1 while maintaining focus on its evidence-based elements. IDSA’s core recommendation is to limit SEP-1 to septic shock, for which the evidence supporting the benefit of immediate antibiotics is greatest. Prompt empiric antibiotics are often appropriate for suspected sepsis without shock, but IDSA believes there is too much heterogeneity and difficulty defining this population, uncertainty about the presence of infection, and insufficient data on the necessity of immediate antibiotics to support a mandatory treatment standard for all patients in this category. IDSA believes guidance on managing possible sepsis without shock is more appropriate for guidelines that can delineate the strengths and limitations of supporting evidence and allow clinicians discretion in applying specific recommendations to individual patients. Removing sepsis without shock from SEP-1 will mitigate the risk of unnecessary antibiotic prescribing for noninfectious syndromes, simplify data abstraction, increase measure reliability, and focus attention on the population most likely to benefit from immediate empiric broad-spectrum antibiotics.
This Infectious Diseases Society of America position paper outlines several recommendations aimed at reducing the risk of unintended consequences from the national Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) quality measure, while maintaining focus on its evidence-based elements.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciaa059</identifier><identifier>PMID: 32374861</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Aged ; Anti-Bacterial Agents - therapeutic use ; Communicable Diseases - drug therapy ; Humans ; Major and Commentaries ; Medicare ; Quality Indicators, Health Care ; Reproducibility of Results ; Sepsis - diagnosis ; Sepsis - drug therapy ; Shock, Septic - diagnosis ; Shock, Septic - drug therapy ; United States</subject><ispartof>Clinical infectious diseases, 2021-02, Vol.72 (4), p.541-552</ispartof><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2020. 2020</rights><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-2a94e61bc2f283a4d2f3b300603ae9c4665a98b69f059c614ec13213dde4d1d3</citedby><cites>FETCH-LOGICAL-c412t-2a94e61bc2f283a4d2f3b300603ae9c4665a98b69f059c614ec13213dde4d1d3</cites><orcidid>0000-0002-6489-6294 ; 0000-0002-4420-9004</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32374861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rhee, Chanu</creatorcontrib><creatorcontrib>Chiotos, Kathleen</creatorcontrib><creatorcontrib>Cosgrove, Sara E</creatorcontrib><creatorcontrib>Heil, Emily L</creatorcontrib><creatorcontrib>Kadri, Sameer S</creatorcontrib><creatorcontrib>Kalil, Andre C</creatorcontrib><creatorcontrib>Gilbert, David N</creatorcontrib><creatorcontrib>Masur, Henry</creatorcontrib><creatorcontrib>Septimus, Edward J</creatorcontrib><creatorcontrib>Sweeney, Daniel A</creatorcontrib><creatorcontrib>Strich, Jeffrey R</creatorcontrib><creatorcontrib>Winslow, Dean L</creatorcontrib><creatorcontrib>Klompas, Michael</creatorcontrib><title>Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract
The Centers for Medicare & Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concerned about SEP-1’s potential to drive antibiotic overuse because it does not account for the high rate of sepsis overdiagnosis and encourages aggressive antibiotics for all patients with possible sepsis, regardless of the certainty of diagnosis or severity of illness. IDSA is also concerned that SEP-1’s complex “time zero” definition is not evidence-based and is prone to inter-observer variation. In this position paper, IDSA outlines several recommendations aimed at reducing the risk of unintended consequences of SEP-1 while maintaining focus on its evidence-based elements. IDSA’s core recommendation is to limit SEP-1 to septic shock, for which the evidence supporting the benefit of immediate antibiotics is greatest. Prompt empiric antibiotics are often appropriate for suspected sepsis without shock, but IDSA believes there is too much heterogeneity and difficulty defining this population, uncertainty about the presence of infection, and insufficient data on the necessity of immediate antibiotics to support a mandatory treatment standard for all patients in this category. IDSA believes guidance on managing possible sepsis without shock is more appropriate for guidelines that can delineate the strengths and limitations of supporting evidence and allow clinicians discretion in applying specific recommendations to individual patients. Removing sepsis without shock from SEP-1 will mitigate the risk of unnecessary antibiotic prescribing for noninfectious syndromes, simplify data abstraction, increase measure reliability, and focus attention on the population most likely to benefit from immediate empiric broad-spectrum antibiotics.
This Infectious Diseases Society of America position paper outlines several recommendations aimed at reducing the risk of unintended consequences from the national Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) quality measure, while maintaining focus on its evidence-based elements.</description><subject>Aged</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Communicable Diseases - drug therapy</subject><subject>Humans</subject><subject>Major and Commentaries</subject><subject>Medicare</subject><subject>Quality Indicators, Health Care</subject><subject>Reproducibility of Results</subject><subject>Sepsis - diagnosis</subject><subject>Sepsis - drug therapy</subject><subject>Shock, Septic - diagnosis</subject><subject>Shock, Septic - drug therapy</subject><subject>United States</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxSMEoqVw4o58QkUo4D-J1-4BqZQFKrWwsL1bs_aka0jiYCcr7dfiE-LVbiu4cLBmpPn5zdO8onjO6BtGtXhrvcsPgNb6QXHMajErZa3Zw9zTWpWVEuqoeJLSD0oZU7R-XBwJLmaVkuy4-H3ZN2hHH6ZEPviEkDCRZbAexy0JDTnvMHoLZBGSz1RPFjBgPCPf0Yauw96hy_3GpzxLZAxkXCP5AjsUWrLEDUbMZUg-Eejdrh29Jct1sD_JHGK7JdfQwy1mrZG8n3rXIjldzhcle3X379sErc92rrO7KeLT4lEDbcJnh3pS3Hyc31x8Lq--frq8OL8qbcX4WHLQFUq2srzhSkDleCNWglJJBaC2lZQ1aLWSusmHs5JVaJngTDiHlWNOnBTv9rLDtOrQ2ewvQmuG6DuIWxPAm38nvV-b27AxiiktFc8CpweBGH5NmEbT-WSxbaHHfG7DhdY5m3qmMvp6j9oYUorY3K9h1OxCNjlkcwg50y_-dnbP3qWagZd7IEzDf5X-AM1Gs_c</recordid><startdate>20210216</startdate><enddate>20210216</enddate><creator>Rhee, Chanu</creator><creator>Chiotos, Kathleen</creator><creator>Cosgrove, Sara E</creator><creator>Heil, Emily L</creator><creator>Kadri, Sameer S</creator><creator>Kalil, Andre C</creator><creator>Gilbert, David N</creator><creator>Masur, Henry</creator><creator>Septimus, Edward J</creator><creator>Sweeney, Daniel A</creator><creator>Strich, Jeffrey R</creator><creator>Winslow, Dean L</creator><creator>Klompas, Michael</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6489-6294</orcidid><orcidid>https://orcid.org/0000-0002-4420-9004</orcidid></search><sort><creationdate>20210216</creationdate><title>Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure</title><author>Rhee, Chanu ; Chiotos, Kathleen ; Cosgrove, Sara E ; Heil, Emily L ; Kadri, Sameer S ; Kalil, Andre C ; Gilbert, David N ; Masur, Henry ; Septimus, Edward J ; Sweeney, Daniel A ; Strich, Jeffrey R ; Winslow, Dean L ; Klompas, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-2a94e61bc2f283a4d2f3b300603ae9c4665a98b69f059c614ec13213dde4d1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Communicable Diseases - drug therapy</topic><topic>Humans</topic><topic>Major and Commentaries</topic><topic>Medicare</topic><topic>Quality Indicators, Health Care</topic><topic>Reproducibility of Results</topic><topic>Sepsis - diagnosis</topic><topic>Sepsis - drug therapy</topic><topic>Shock, Septic - diagnosis</topic><topic>Shock, Septic - drug therapy</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rhee, Chanu</creatorcontrib><creatorcontrib>Chiotos, Kathleen</creatorcontrib><creatorcontrib>Cosgrove, Sara E</creatorcontrib><creatorcontrib>Heil, Emily L</creatorcontrib><creatorcontrib>Kadri, Sameer S</creatorcontrib><creatorcontrib>Kalil, Andre C</creatorcontrib><creatorcontrib>Gilbert, David N</creatorcontrib><creatorcontrib>Masur, Henry</creatorcontrib><creatorcontrib>Septimus, Edward J</creatorcontrib><creatorcontrib>Sweeney, Daniel A</creatorcontrib><creatorcontrib>Strich, Jeffrey R</creatorcontrib><creatorcontrib>Winslow, Dean L</creatorcontrib><creatorcontrib>Klompas, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rhee, Chanu</au><au>Chiotos, Kathleen</au><au>Cosgrove, Sara E</au><au>Heil, Emily L</au><au>Kadri, Sameer S</au><au>Kalil, Andre C</au><au>Gilbert, David N</au><au>Masur, Henry</au><au>Septimus, Edward J</au><au>Sweeney, Daniel A</au><au>Strich, Jeffrey R</au><au>Winslow, Dean L</au><au>Klompas, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2021-02-16</date><risdate>2021</risdate><volume>72</volume><issue>4</issue><spage>541</spage><epage>552</epage><pages>541-552</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Abstract
The Centers for Medicare & Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concerned about SEP-1’s potential to drive antibiotic overuse because it does not account for the high rate of sepsis overdiagnosis and encourages aggressive antibiotics for all patients with possible sepsis, regardless of the certainty of diagnosis or severity of illness. IDSA is also concerned that SEP-1’s complex “time zero” definition is not evidence-based and is prone to inter-observer variation. In this position paper, IDSA outlines several recommendations aimed at reducing the risk of unintended consequences of SEP-1 while maintaining focus on its evidence-based elements. IDSA’s core recommendation is to limit SEP-1 to septic shock, for which the evidence supporting the benefit of immediate antibiotics is greatest. Prompt empiric antibiotics are often appropriate for suspected sepsis without shock, but IDSA believes there is too much heterogeneity and difficulty defining this population, uncertainty about the presence of infection, and insufficient data on the necessity of immediate antibiotics to support a mandatory treatment standard for all patients in this category. IDSA believes guidance on managing possible sepsis without shock is more appropriate for guidelines that can delineate the strengths and limitations of supporting evidence and allow clinicians discretion in applying specific recommendations to individual patients. Removing sepsis without shock from SEP-1 will mitigate the risk of unnecessary antibiotic prescribing for noninfectious syndromes, simplify data abstraction, increase measure reliability, and focus attention on the population most likely to benefit from immediate empiric broad-spectrum antibiotics.
This Infectious Diseases Society of America position paper outlines several recommendations aimed at reducing the risk of unintended consequences from the national Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) quality measure, while maintaining focus on its evidence-based elements.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>32374861</pmid><doi>10.1093/cid/ciaa059</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6489-6294</orcidid><orcidid>https://orcid.org/0000-0002-4420-9004</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1058-4838 |
ispartof | Clinical infectious diseases, 2021-02, Vol.72 (4), p.541-552 |
issn | 1058-4838 1537-6591 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8189682 |
source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Aged Anti-Bacterial Agents - therapeutic use Communicable Diseases - drug therapy Humans Major and Commentaries Medicare Quality Indicators, Health Care Reproducibility of Results Sepsis - diagnosis Sepsis - drug therapy Shock, Septic - diagnosis Shock, Septic - drug therapy United States |
title | Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T19%3A19%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infectious%20Diseases%20Society%20of%20America%20Position%20Paper:%20Recommended%20Revisions%20to%20the%20National%20Severe%20Sepsis%20and%20Septic%20Shock%20Early%20Management%20Bundle%20(SEP-1)%20Sepsis%20Quality%20Measure&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Rhee,%20Chanu&rft.date=2021-02-16&rft.volume=72&rft.issue=4&rft.spage=541&rft.epage=552&rft.pages=541-552&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciaa059&rft_dat=%3Cproquest_pubme%3E2399838578%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2399838578&rft_id=info:pmid/32374861&rft_oup_id=10.1093/cid/ciaa059&rfr_iscdi=true |